BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37217995)

  • 1. The genetic landscape and possible therapeutics of neurofibromatosis type 2.
    Ghalavand MA; Asghari A; Farhadi M; Taghizadeh-Hesary F; Garshasbi M; Falah M
    Cancer Cell Int; 2023 May; 23(1):99. PubMed ID: 37217995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
    Choi JW; Lee JY; Phi JH; Wang KC; Chung HT; Paek SH; Kim DG; Park SH; Kim SK
    J Neurosurg Pediatr; 2014 Jun; 13(6):650-7. PubMed ID: 24724714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in neurofibromatosis type 2 and vestibular schwannoma.
    Ren Y; Chari DA; Vasilijic S; Welling DB; Stankovic KM
    Neurooncol Adv; 2021; 3(1):vdaa153. PubMed ID: 33604573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of multiple tumors in neurofibromatosis type 2 patients.
    Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
    Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.
    Dinh CT; Nisenbaum E; Chyou D; Misztal C; Yan D; Mittal R; Young J; Tekin M; Telischi F; Fernandez-Valle C; Liu XZ
    Otol Neurotol; 2020 Jun; 41(5):e529-e537. PubMed ID: 32150022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
    Sun S; Liu A
    J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress in genomics and targeted therapies for neurofibromatosis type 2.
    Hiruta R; Saito K; Bakhit M; Fujii M
    Fukushima J Med Sci; 2023 Aug; 69(2):95-103. PubMed ID: 37468280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis type 2 (NF2): diagnosis and management.
    Lloyd SK; Evans DG
    Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
    Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
    Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
    Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
    J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
    Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
    J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
    Welling DB
    Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
    Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
    J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis type 2.
    Slattery WH
    Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons.
    Welling DB
    Otolaryngol Clin North Am; 2023 Jun; 56(3):543-556. PubMed ID: 37024334
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.